title: Treatment of hypertension in patients with nondiabetic chronic kidney disease.
abstract: Hypertension is highly prevalent in patients with chronic kidney disease (CKD). As either the cause or the consequence of CKD, hypertension is an important independent factor determining the rate of loss of renal function. Hypertension is also a significant independent risk factor for cardiovascular events in patients with CKD, the leading cause of their morbidity and mortality. Based on evidence from observational cohort studies and randomized clinical trials, the Canadian Hypertension Education Program (CHEP) recommends a target blood pressure (BP) of lower than 130/80 mmHg in hypertensive patients with nondiabetic CKD. The CHEP also endorses the use of renin-angiotensin system blockers for the BP-lowering regimen in nondiabetic patients with CKD and significant proteinuria. It is recognized that the majority of nondiabetic patients with CKD will require two or more BP-lowering drugs to attain target BP. Furthermore, extracellular fluid volume expansion is a major contributor to hypertension in patients with CKD, and diuretics should be part of the BP-lowering regimen in the majority of patients. Patients with CKD are recognized to be at high risk for cardiovascular events, and studies testing new emerging treatments of hypertension to reduce the burden of CKD on renal and cardiovascular outcomes are underway. In this regard, the CHEP will continue to review and update all its recommendations annually.
authors.affiliation: Division of Nephrology, University of Ottawa, Ottawa, Ontario. mruzicka@ottawahospital.on.ca
authors.forename: Marcel
authors.initials: M
authors.lastname: Ruzicka
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Burns
authors.forename: Bruce
authors.initials: B
authors.lastname: Culleton
authors.forename: Sheldon W
authors.initials: SW
authors.lastname: Tobe
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D002908:Chronic Disease; D018450:Disease Progression; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents; D004232:Diuretics